

AVATROMBOPAG tablets (Doptelet® ▼) for chronic immune thrombocytopenia

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of AVATROMBOPAG tablets (Doptelet® ▼) for chronic immune thrombocytopenia.

GREY

Avatrombopag is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids and immunoglobulins).^[1]

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, clinicians should continue to follow national guidance, local pathways and local formulary choices for the treatment of ITP:

- > NHS England Interim Clinical Commissioning Policy: [Thrombopoietin receptor agonists as first line therapy for new or relapsed immune thrombocytopenia in adults and children over the age of 1 year during the COVID-19 pandemic](#) (updated 8 March 2021)
- > Pan Mersey APC Formulary: [Drugs used in platelet disorders](#)

References

1. Swedish Orphan Biovitrum Ltd. Summary of product characteristics; [Doptelet 20 mg film-coated tablets](#), 18 January 2021. Accessed online 18 March 2021.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.